A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815
This study is recruiting at 7 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumor, Adult
- Microsatellite Stable Colorectal Cancer
- Head and Neck Squamous Cell Carcinoma
- Cervical Cancer
- Kidney Cancer
- Renal Cell Carcinoma
- Melanoma Stage IV
- Merkel Cell Carcinoma of Skin
- Mesothelioma
- Non-small Cell Lung Cancer
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Urothelial Carcinoma Bladder
- Squamous Cell Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- KaliVir Immunotherapeutics
- Last updated on ClinicalTrials.gov
- April 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- USC/Norris Comprehensive Cancer Center · Los Angeles, CA
- UC Irvine Health · Orange, CA
Florida · 1
- University of Miami · Miami, FL
Indiana · 1
- Community Health Network · Indianapolis, IN
Pennsylvania · 1
- UPMC- Hillman Cancer Center · Pittsburgh, PA
Texas · 2
- Mary Crowley Cancer Research · Dallas, TX
- University of Texas MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.